Novartis pelacarsen misses primary endpoint in Phase 3 study
Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce cardiovascular events versus placebo.
Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study. The company said on Friday that pelacarsen did not cut the risk of cardiovascular events, including deaths, heart attacks and strokes, versus placebo. The drug did succeed…